biostudies-literatureUnknown4(4)Schmitz-Winnenthal FHVEGFR-2 is expressed on tumor vasculature and a target for anti-angiogenic intervention. VXM01 is a first in kind orally applied tumor vaccine based on live, attenuated Salmonella bacteria carrying an expression plasmid, encoding VEGFR-2. We here studied the safety, tolerability, T effector (Teff), T regulatory (Treg) and humoral responses to VEGFR2 and anti-angiogenic effects in advanced pancreatic cancer patients in a randomized, dose escalation phase I clinical trial. Results of the first 3 mo observation period are reported. Locally advanced or metastatic, pancreatic cancer patients were enrolled. In five escalating dose groups, 30 patients received VXM01 and 15 placebo on days 1, 3, 5, and 7. Treatment was well tolerated at all dose levels. No dose-limiting toxicities were observed. SOncoimmunologye1001217https://www.ebi.ac.uk/biostudies/studies/S-EPMC4485742biostudies-literatureAnti-angiogenic activity of VXM01, an oral T-cell vaccine against VEGF receptor 2, in patients with advanced pancreatic cancer: A randomized, placebo-controlled, phase 1 trial.PMC4485742Niethammer AGSpringer MKoc RStamova SSchimmack SPianka FGrenacher LSisic LSchmitz-Winnenthal FHGe YHohmann NUlrich ASchmidt TKeller AVKnebel PHaefeli WESpringfeld CLeowardi CLubenau HPodola LKlaiber UMikus GBucur MBeckhove PBuechler MWBreiner KMDiener MWeitz JFriedrich TfalseAnti-angiogenic activity of VXM01, an oral T-cell vaccine against VEGF receptor 2, in patients with advanced pancreatic cancer: A randomized, placebo-controlled, phase 1 trial.VEGFR-2 is expressed on tumor vasculature and a target for anti-angiogenic intervention. VXM01 is a first in kind orally applied tumor vaccine based on live, attenuated Salmonella bacteria carrying an expression plasmid, encoding VEGFR-2. We here studied the safety, tolerability, T effector (Teff), T regulatory (Treg) and humoral responses to VEGFR2 and anti-angiogenic effects in advanced pancreatic cancer patients in a randomized, dose escalation phase I clinical trial. Results of the first 3 mo observation period are reported. Locally advanced or metastatic, pancreatic cancer patients were enrolled. In five escalating dose groups, 30 patients received VXM01 and 15 placebo on days 1, 3, 5, and 7. Treatment was well tolerated at all dose levels. No dose-limiting toxicities were observed. S2015-01-01T00:00:00Z2015 Apr2026-04-08T16:24:29.015Z2019-03-27T01:54:15ZS-EPMC44857422613739710.1080/2162402X.2014.100121710.1080/2162402x.2014.1001217